Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * FRESENIUS MEDICAL CARE HOLDINGS INC /NY/ 2. Issuer Name and Ticker or Trading Symbol Humacyte, Inc. [HUMA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner _____ Officer (give title below) __X__ Other (specify below) Former 10% Shareholder (Last) (First) (Middle) 920 WINTER STREET 3. Date of Earliest Transaction (Month/Day/Year) 08/26/2021 (Street) WALTHAM, MA 02451-1547 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, par value $0.0001 per share 18,312,735(1)(2) D(3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
FRESENIUS MEDICAL CARE HOLDINGS INC /NY/ 920 WINTER STREET WALTHAM, MA 02451-1547				Former 10% Shareholder

Signatures

Fresenius Medical Care Holdings, Inc. /s/ Bryan Mello By: Bryan Mello Vice President and Asst. Treasurer		12/08/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Excludes the Reporting Person's pro rata share of up to 15,000,000 additional shares of the Issuer's Common Stock which may become issuable to the former shareholders of Humacyte, Inc. pursuant to the terms of the Business Combination Agreement dated as of February 17, 2021 by and among the Issuer, Hunter Merger Sub, Inc. and Humacyte, Inc., as to which the Reporting Person disclaims any present beneficial ownership interest.
(2)	This Form 4 is being filed solely to report that the Reporting Person is no longer subject to Section 16. (See the checkbox on page 1.) The decrease in the Reporting Person's beneficial ownership to less than 10% is solely the result of an increase in the number of outstanding shares of the Issuer's Common Stock subsequent to the filing of the Reporting Person's Initial Statement of Beneficial Ownership on Form 3. Neither of the Reporting Person nor FME (see note 3) has disposed of or acquired any shares of the Issuer's Common Stock subsequent to the filing of such Form 3 on September 2, 2021.
(3)	Fresenius Medical Care Holdings, Inc. is an indirect, wholly-owned subsidiary of Fresenius Medical Care AG ("FME"). FME's address is Else-Kroner Strasse 1, 61352 Bad Homburg, Germany.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.